Business Context and Reporting Period
This Form 8-K Current Report from Aptevo Therapeutics Inc. (APVO) covers the event date of March 5, 2024. The filing details the implementation of a reverse stock split approved by stockholders and the Board of Directors to maintain compliance with Nasdaq listing standards.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split: A 1-for-44 reverse stock split of outstanding common stock became effective at 5:01 p.m. Eastern Time on March 5, 2024.
- Share Consolidation: Every 44 shares of issued and outstanding common stock were automatically combined into one share without a change in par value.
- Trading Resumption: The stock began trading on a split-adjusted basis on The Nasdaq Capital Market on March 6, 2024.
- New CUSIP: The new CUSIP number for the common stock is 03835L 306.
- Equity Adjustments: Proportionate adjustments were made to the exercise prices and share counts for outstanding stock options, restricted stock units (RSUs), and warrants. The number of shares reserved under equity compensation plans was reduced proportionately.
- Fractional Shares: No fractional shares were issued; stockholders entitled to fractional shares received cash payments in lieu thereof.
Guidance, Outlook, and Risks
The filing includes forward-looking statements regarding the reverse stock split, noting that actual results may differ due to risks such as delays in regulatory approvals. The Company disclaims any obligation to update these statements. No specific financial guidance or management commentary on operational outlook is provided in this document.
Investor Verification Checklist
- Verify the new CUSIP number (03835L 306) for trading and settlement purposes.
- Confirm the adjusted number of shares held and the new exercise prices for any outstanding options or warrants.
- Check for cash payments received in lieu of fractional shares.
- Review the Company's subsequent filings to ensure continued compliance with Nasdaq listing requirements post-split.